Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Proof of Concept of the Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease

NCT06400368 is registered in ClinicalTrials.gov with NeuroVision Imaging as lead sponsor.

NCT NCT06400368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06400368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Proof of Concept of the Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease
Lead sponsor
NeuroVision Imaging
Phase
Observational
Overall status
Unknown status
Start date
April 24, 2024
Completion date
April 30, 2026
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, mild cognitive impairment